112 STAT. 2681-687 PUBLIC LAW 105-277—OCT. 21, 1998 (2) State and local law enforcement agencies have committed resources to respond to the drug trafficking problem in the area, thereby indicating a determination to respond aggressively to the problem; (3) drug-related activities in the area are having a harmful impact in other areas of the country; and (4) a significant increase in allocation of Federal resources is necessary to respond adequately to drug-related activities in the area. (d) USE OF FUNDS.—The Director shall ensure that no Federal funds appropriated for the High Intensity Drug Trafficking Program are expended for the establishment or expansion of drug treatment programs. 21 USC 1707. SEC. 708. COUNTER-DRUG TECHNOLOGY ASSESSMENT CENTER. (a) ESTABLISHMENT. —T here is established within the Office the Counter-Drug Technology Assessment Center (referred to in this section as the "Center"). The Center shall operate under the authority of the Director of National Drug Control Policy and shall serve as the central counter-drug technology research and development organization of the United States Government. (b) DIRECTOR OF TECHNOLOGY. —T here shall be at the head of the Center the Director of Technology, who shall be appointed by the Director of National Drug Control Policy from among individuals qualified and distinguished in the area of science, medicine, engineering, or technology. (c) ADDITIONAL RESPONSIBILITIES OF THE DIRECTOR OF NATIONAL DRUG CONTROL POLICY.— (1) IN GENERAL.— The Director, acting through the Director of Technology shall— (A) identify and define the short-, medium-, and longterm scientific and technological needs of Federal, State, and local drug supply reduction agencies, including— (i) advanced surveillance, tracking, and radar imaging; (ii) electronic support measures; (iii) communications; (iv) data fusion, advanced computer systems, and artificial intelligence; and (v) chemical, biological, radiological (including neutron, electron, and graviton), and other means of detection; (B) identify demand reduction basic and applied research needs and initiatives, in consultation with affected National Drug Control Program agencies, including— (i) improving treatment through neuroscientific advances; (ii) improving the transfer of biomedical research to the clinical setting; and (iii) in consultation with the National Institute on Drug Abuse, and through interagency agreements or grants, examining addiction and rehabilitation research and the application of technology to expanding the effectiveness or availability of drug treatment; (C) make a priority ranking of such needs identified in subparagraphs (A) and (B) according to fiscal and
�
